Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia

Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Mistry, Jayna J, Hellmich, Charlotte, Lambert, Amelia, Moore, Jamie A, Jibril, Aisha, Collins, Angela, Bowles, Kristian M, Rushworth, Stuart A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117650/
https://www.ncbi.nlm.nih.gov/pubmed/33985565
http://dx.doi.org/10.1186/s40364-021-00291-y
_version_ 1783691625079242752
author Mistry, Jayna J
Hellmich, Charlotte
Lambert, Amelia
Moore, Jamie A
Jibril, Aisha
Collins, Angela
Bowles, Kristian M
Rushworth, Stuart A
author_facet Mistry, Jayna J
Hellmich, Charlotte
Lambert, Amelia
Moore, Jamie A
Jibril, Aisha
Collins, Angela
Bowles, Kristian M
Rushworth, Stuart A
author_sort Mistry, Jayna J
collection PubMed
description Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resulted in a slower tumor progression and a reduced leukemia growth both in vitro and in vivo. These data provide evidence for clinical evaluation of Venetoclax and Daratumumab combination in the treatment of AML. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-021-00291-y.
format Online
Article
Text
id pubmed-8117650
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81176502021-05-17 Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia Mistry, Jayna J Hellmich, Charlotte Lambert, Amelia Moore, Jamie A Jibril, Aisha Collins, Angela Bowles, Kristian M Rushworth, Stuart A Biomark Res Letter to the Editor Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resulted in a slower tumor progression and a reduced leukemia growth both in vitro and in vivo. These data provide evidence for clinical evaluation of Venetoclax and Daratumumab combination in the treatment of AML. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-021-00291-y. BioMed Central 2021-05-13 /pmc/articles/PMC8117650/ /pubmed/33985565 http://dx.doi.org/10.1186/s40364-021-00291-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter to the Editor
Mistry, Jayna J
Hellmich, Charlotte
Lambert, Amelia
Moore, Jamie A
Jibril, Aisha
Collins, Angela
Bowles, Kristian M
Rushworth, Stuart A
Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
title Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
title_full Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
title_fullStr Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
title_full_unstemmed Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
title_short Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
title_sort venetoclax and daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of acute myeloid leukemia
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117650/
https://www.ncbi.nlm.nih.gov/pubmed/33985565
http://dx.doi.org/10.1186/s40364-021-00291-y
work_keys_str_mv AT mistryjaynaj venetoclaxanddaratumumabcombinationtreatmentdemonstratespreclinicalefficacyinmousemodelsofacutemyeloidleukemia
AT hellmichcharlotte venetoclaxanddaratumumabcombinationtreatmentdemonstratespreclinicalefficacyinmousemodelsofacutemyeloidleukemia
AT lambertamelia venetoclaxanddaratumumabcombinationtreatmentdemonstratespreclinicalefficacyinmousemodelsofacutemyeloidleukemia
AT moorejamiea venetoclaxanddaratumumabcombinationtreatmentdemonstratespreclinicalefficacyinmousemodelsofacutemyeloidleukemia
AT jibrilaisha venetoclaxanddaratumumabcombinationtreatmentdemonstratespreclinicalefficacyinmousemodelsofacutemyeloidleukemia
AT collinsangela venetoclaxanddaratumumabcombinationtreatmentdemonstratespreclinicalefficacyinmousemodelsofacutemyeloidleukemia
AT bowleskristianm venetoclaxanddaratumumabcombinationtreatmentdemonstratespreclinicalefficacyinmousemodelsofacutemyeloidleukemia
AT rushworthstuarta venetoclaxanddaratumumabcombinationtreatmentdemonstratespreclinicalefficacyinmousemodelsofacutemyeloidleukemia

Ejemplares similares